Safety and Pharmacokinetics of MCI-186 in Subjects With Acute Ischemic Stroke

Acute Ischemic Stroke (AIS) Clinical Trial

Official title:
A Phase IIa, Multi-centre, Randomised, Double-blind, Placebo Controlled, Clinical Study Investigating the Safety, Tolerability and Pharmacokinetics of MCI-186 in Subjects With Acute Ischemic Stroke

Status Completed

Clinical Trial Summary

The objectives of this study are to assess the safety, tolerability and local tolerance, and to investigate the plasma levels and terminal elimination half life of MCI-186, and to review the routine clinical and neurological assessments data of MCI-186 in subjects with acute ischemic stroke.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00821821
Study type	Interventional
Source	Mitsubishi Tanabe Pharma Corporation
Contact
Status	Completed
Phase	Phase 2
Start date	February 2009
Completion date	November 2010

View Details

See also
	Status	Clinical Trial	Phase
	Recruiting	`NCT05585606` - Study of the Safety and Neuroprotective Capacity of Scp776 in Acute Ischemic Stroke	Phase 2
	Completed	`NCT05838456` - Deep Learning Enabled Endovascular Stroke Therapy Screening in Community Hospitals	N/A